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Abstract
Background: Deep and superficial sternal wound infections (DSWI & SWI) following cardiac surgery increase
morbidity, mortality and cost. Autologous platelet rich plasma (PRP) derived from the patient’s own blood has
been used in other surgical settings to promote successful wound healing. The goal of this study was to analyze
the addition of PRP using a rapid point of care bedside system to standard wound care in all patients undergoing
sternotomy for cardiac surgical procedures.
Methods: Over a 7 year period, 2000 patients undergoing open cardiac operations requiring sternotomy were
enrolled. One thousand patients received standard of care sternal closure. The other 1000 patients received
standard of care sternal closure plus PRP applied to the sternum at the time of closure. The outcomes related to
wound healing, infection, readmissions, and costs were analyzed.
Results: In the 2000 patients, there were more ventricular assist device implants/heart transplants and emergency
operations in the PRP group; otherwise there were no significant differences. The use of PRP reduced the incidence
of DSWI from 2.0 to 0.6 %, SWI from 8.0 to 2.0 %, and the readmission rate from 4.0 to 0.8 %. The use of PRP
reduced the costs associated with the development of deep and superficial wound complications from $1,256,960
to $593,791.
Conclusions: The use of PRP decreases the incidence and costs of sternal wound complications following cardiac
surgery. The routine use of platelet rich plasma should be considered for all patients undergoing sternotomy for
cardiac surgical procedures.
Trial registration: Clinicaltrials.gov (NCT00130377) for the data registry.
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Background
Sternal wound complications such as dehiscence and
infection following median sternotomy occurs in 0.2 to
8 % of patients undergoing cardiac surgery [1]. These
post-surgical complications remain a significant source of
mortality, and treatment entails extended hospitalization,
long-term antibiotics, multiple operative procedures, and
high cost. Several patient and surgical related risk factors
for the development of sternal wound complications have
been identified [2, 3]: obesity, bilateral harvesting of
the internal mammary artery, diabetes, steroid treatment,
advanced age, active smoking, osteoporosis, and chronic
lung disease. Several therapeutic strategies have been used
to minimize the incidence of deep sternal wound infec-
tions (DSWI) in high-risk patients [4]. However, once a
DSWI occurs, debridement, continuous antibiotic irriga-
tion, and vacuum-assisted closure therapy procedures
have decreased the incidence of DSWI related mortality
[5–7]. A preventative therapeutic strategy has yet to be
clearly identified. The topical application of autologous
platelet rich plasma (PRP) to promote earlier wound heal-
ing in a variety of settings has been described [8]. Several
recent reports have demonstrated the benefits of using the
topical application of PRP for improved postoperative
outcomes following median sternotomy [9–11]. Most of
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these studies, however, have been under-powered and
have no financial analysis of the potential cost savings
associated with the use of PRP therapy. Currently, the
Centers for Medicaid and Medicare Services do not reim-
burse for the costs incurred during the treatment of
DSWI. Metrics such as quality now help determine reim-
bursement in the value based system of healthcare. Our
goal in this outcomes study was to determine the inci-
dence and costs of sternal wound complications in 1000
consecutive patients undergoing sternotomy for cardiac
surgery procedures that received PRP and compare them
to 1000 patients that did not receive PRP.
Methods
Patients
Between January 2005 and January 2013, 2000 consecutive
patients undergoing open cardiac surgery requiring a
sternotomy at a single cardiac surgical center were con-
sented and were included in our database (NCT00130377).
University of Utah IRB approval #35242. The data was also
prospectively collected as part of the Society of Thoracic
Surgeons database at our institution. There were 1000 con-
secutive patients who received standard of care sternal clos-
ure plus PRP composed of autologous platelet rich plasma,
calcium and thrombin applied to the sternum at the time
of closure from December 2009 to January 2013 (PRP).
These patients were compared to the previous one
thousand consecutive patients who received standard of
care sternal closure, including preoperative antibiotics and
protocol driven glycemic management from January 2005
to November 2009 (Control). All data was prospectively
collected and retrospectively analyzed. The outcomes re-
lated to deep and/or superficial sternal wound infections,
readmissions, and actual costs were analyzed for 6 months
post-surgery (Fig. 1). Sternal wound infections were
characterized by the Centers for Disease Control and
Prevention (CDC) definitions: superficial, deep, or organ/
space surgical site infections [12]. All patients received stan-
dardized preoperative intravenous antibiotics within 60 min
of the procedure. The preoperative antibiotics protocol and
glycemic management protocol were standard and re-
mained the same for all patients throughout the study.
Standard surgical methods were used for the performance
of all median sternotomies and sternal closures. All patients
undergoing sternotomy were included in the study includ-
ing emergencies, reoperations, ventricular assist device
implantations, heart transplants, aortic dissections and
standard operations (i.e. coronary artery bypass grafting
and valve repairs or replacements). Matching or controlling
of only a subset of patients was not performed as to avoid
selection bias (Table 1).
Study design and endpoints
All data was collected prospectively and analyzed retro-
spectively for this consecutive non-randomized group of
patients. Readmissions, sternal wound infections and
costs were independently verified via the hospital infec-
tion committee and financial office. All patients under-
going sternotomy were included in the study.
Definitions
The diagnosis of DSWI was made, based on the guide-




























Fig. 1 Time to infection post-surgery. The time to infection post-
surgery was reported as number of patients with infections. PRP
DSWI- platelet rich plasma deep sternal wound infection, Control
DSWI – control with deep sternal wound infection, PRP SSWI- platelet
rich plasma superficial sternal wound infection, Control SSWI – control
with superficial sternal wound infection






Age 69.7 ± 14 71.5 ± 16 0.0075
Smoker 223 257 0.17
Male/female 811 845 0.55
Body surface area 1.7 ± 0.8 1.9 ± 0.5 0.0001
COPD 192 211 0.41
Chronic renal insufficiency - Dialysis 155 176 0.29
Osteoporosis 118 112 0.79
Oral Steroids 72 93 0.12
Hypertension 659 688 0.55
Diabetes mellitus 267 246 0.43
Ventricular Assist Device/Transplant 96 198 0.0001
CABG with BIMA 11 23 0.056
Emergency Surgery 9 142 0.0018
Urgent Surgery 422 476 0.14
Prior Sternotomy 226 271 0.071
Mean PRBCs transfused 1.5 ± 0.7 1.9 ± 1.5 0.0001
Re-exploration for Bleeding 83 67 0.24
Intubation >24 h 301 344 0.15
PRP platelet rich plasma, COPD chronic obstructive pulmonary disease, CABG
coronary artery bypass grafting, BIMA bilateral internal mammary arteries,
PRBC-packed red blood cells
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more of the following: [1] positive culture of mediastinal
tissue or fluid; [2] clinical evidence of mediastinitis dur-
ing sternal reoperation; or [3] chest pain, sternal instabil-
ity, purulent discharge from the mediastinum associated
with a positive blood culture.
Standard sternal closure
All sternotomies were made midline with a sternal saw
blade. The sternum was closed with simple interrupted
or figure of eight stainless steel wire. The wounds were
closed in a layered manner with absorbable suture. The
wounds were dressed with Steri-Strips™ (3 M Nexcare,
St. Paul, MN), gauze and paper tape. All surgeons at our
institution participated in study. Residents and fellows
were included in the sternal closure process.
Platelet rich plasma (PRP) preparation and application
In the treatment population, 52 mL of whole blood was
drawn prior to surgery via a central venous line and
mixed with 8 mL of the anticoagulant citrate dextrose
formula A. The anticoagulated blood (60 mL) was then
processed using the Magellan® Autologous Platelet Sep-
arator System which is FDA approved to make platelet
rich plasma (Arteriocyte Medical Systems, Cleveland,
Ohio). The cost of the PRP kit is $385.00. The auto-
mated processing time was 15 min which did not require
supervision. After this process was finished an audible
sound verified completion. There was 6 mL of PRP pro-
duced for each patient to be applied to sternum and soft
tissue during sternal closure. The analysis of the growth
factors is shown in Table 2. The prepared PRP was ap-
plied with calcium chloride and thrombin topically onto
the exposed sternal edges and the subcutaneous tissue of
the chest wound at the time of closure with 6 mL PRP
to 1 mL calcium/thrombin ratio. The procedure time for
application was 30 s.
Cost analysis
The cost of the PRP procedure included the cost of the
disposables. These were actual costs and not hospital
charges. These costs were validated by the hospital oper-
ating room services director, vendor and hospital finance
department. The costs associated with readmission and
re-intervention were verified with the hospital operating
room services director and the hospital finance depart-
ment. There was no separate cost allocated to the 30 s
for the application of the PRP. Also, the 30 s needed to
procure the blood after central venous catheter insertion
was not accounted for as the blood draw was included
with the standard set of pre-operative laboratory chemis-
tries and other studies.
Statistical analysis
All patients undergoing open cardiac surgery between
January 2005 and January 2013 who met the inclusion
criteria were enrolled in the study. The association of
the application of PRP, patient care costs and patient
outcomes were examined using Fisher’s exact test. Also,
the number of patients needed to be treated to see a
clinical and cost benefit were calculated.
Ethics, consent and permissions: All procedures per-
formed in studies involving human participants were in
accordance with the ethical standards of the institutional
and/or national research committee and with the 1964
Helsinki declaration and its later amendments or com-
parable ethical standards.
Results
Two thousand consecutive patients completed the study.
One thousand of these patients received PRP (PRP group)
while the other 1000 patients did not receive PRP (control
group). There were significant differences between the
two groups with regards to age and body surface area be-
ing lower in the control group and more VAD implanta-
tions/heart transplants, emergency operations and greater
blood transfusion usage in the PRP group. Compared to
the control group, the use of PRP reduced the incidence
of deep sternal wound infection from 2.0 to 0.6 %, superfi-
cial wound drainage from 8.0 to 2.0 %, and the hospital re-
admission rate within 30 days of operation from 4.0 to 0.8.
The time to infection post-surgery demonstrated that all
infections in the PRP group occurred in the first 2 months
post-surgery whereas in the control group occurred up to
4 months post-surgery Fig. 1. There was a significant re-
duction in the overall actual cost in the total management
of deep and superficial wounds ($1,256,960 in the control
group vs $593,791 in the PRP group), Table 3. Despite the
significant overall reduction in cost in the management of
sternal wounds, the number of patients needed to treat to
see a benefit is 71 with 95 % confidence interval 41.8 to
244.5 with a cost of $27,000 to prevent one deep sternal
wound infection and cost break-even point. However, with
superficial sternal wounds the number of patients needed
to treat to see a benefit is 17 with 95 % confidence interval
Table 2 Platelet analysis
Mean ± SD Baseline (60 mL) PRP (mL)
PDGF AB (ng/mL) 8.4 ± 2.1 96.1 ± 22.5
PDGF AA (ng/mL) 2.1 ± 0.4 25.4 ± 3.9
PDGF BB (ng/mL) 5.9 ± 1.2 61.3 ± 11.6
TGF B1 (ng/mL) 46.4 ± 4.4 278.2 ± 38.4
VEGF (ng/mL) 76.3 ± 19.5 801 ± 266.1
bFGF (ng/mL) 15.6 ± 2.9 55.1 ± 9.6
EGF (ng/mL) 13.4 ± 2.1 187 ± 29.4
Platelets were analyzed pre and post concentration for growth factors. PDGF
platelet derived growth factor, TGF transforming growth factor, VEGF vascular
endothelial growth factor, FGF- fibroblast growth factor, EGF endothelial
growth factor
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12.7 to 24.3 with a cost of $6417 to prevent one infection
but cost break-even point does not exist. The overall num-
ber of patients needed to treat to see a benefit is 14 with
95 % confidence interval 10.5 to 18.9 with a cost of $5203
to prevent one overall wound infection and cost break-
even point.
Discussion
Median sternotomy remains the preferred access to the
heart for most cardiac surgery operations [13]. Deep
sternal wound infection (DSWI) following median ster-
notomy, however, remains a life threatening complica-
tion. The ability to reduce DSWI after an operation as
common as open heart surgery has important implica-
tions for patients, caregivers, hospitals and payers. While
advances in surgical debridement, continuous antibiotic
irrigation, flap closure and modern VAC therapy [5–7]
have improved DSWI related mortality over the last
30 years, the incidence of sternal wound complications
has not changed since the 1980s. As a result of this, the
goal would be to prevent to DSWI. There have been a
number of approaches including sternal wrapping, vests,
and increasing the number of sternal wires used during
closure all with limited results [14–16]. There have also
been validated risk models to help predict sternal wound
issues but not to prevent them [17].
The use of autologous PRP for the prevention of
DSWI has been proposed with good clinical results [8].
It is believed that healing following median sternotomy
is improved by growth factors released by the PRP.
During the inflammatory phase of tissue healing, acti-
vated platelets release specific growth factors, such as
transforming growth factors-beta, vascular endothelial
growth factor and epithelial growth factor (Table 2).
These factors stimulate cell proliferation, migration,
differentiation, and matrix synthesis. These same factors
can affect chondrocyte metabolism, chondrogenesis, and
improve bone healing and regeneration [8]. The combin-
ation of growth factors contained in the PRP which are
released onto the surgical site are the proposed mechan-
ism of action to improved sternal wound healing.
PRP has been used in a number of surgical applica-
tions (plastic, maxillofacial and orthopedic surgery) to
promote wound and tissue healing [8, 18]. In addition,
Staphylococcus aureus, the most common bacteria re-
sponsible for DSWI can be inhibited by the application
of PRP [19]. Several studies have proposed the use of au-
tologous PRP application prior to wound closure in car-
diac surgeries with mixed results [20–23]. These studies,
although prospective in design, were underpowered to
effectively evaluate any treatment effects, due to the
small number of patients enrolled. Previous studies re-
port that different methods of producing PRP will result
in varying growth factor levels and compositions [24].
Also, the addition of antibiotics to PRP has also been to
have positive results but unknown if these are incremen-
tal over PRP alone [25]. The use of an automated single
device like the one used in this study provides consistent
platelet concentration, reproducible results independent
of operator and a closed system, reducing the potential
for contamination.
This is the first large clinical study to include all pa-
tients undergoing median sternotomy independent of
emergency status, ventricular assist device implantation,
heart transplant, type of surgery, dialysis, steroid use,
emphysema, or reoperative surgery. Despite some stud-
ies and the Society of Thoracic Surgeons database re-
sults reporting DSWI rates as low as 0.3 %, these do not
account for all patients undergoing median sternotomy.
Most of these studies evaluate elective patients undergo-
ing coronary artery bypass grafting or isolated valve sur-
gery. Also, most studies and/or databases do not report
wound outcomes through 6 months post-operatively as
our study reports. This would account for the higher
wound related infection rates that we report, as up to
40 % of wound complications can occur after 30 days
post-surgery [26]. There was also no difference between
sternal closure with simple sternal wire or figure of eight
sternal wire closure. Also, there were no complications
which were attributed to the use of PRP. This study also
demonstrates that all infections in the PRP group occur
in the first 2 months post-surgery whereas up to 4 months
post-surgery in the control group. Even though the study
was not powered to validate this finding, it may be in-
ferred that PRP leads to earlier healing of the wound and
thus reducing the rate of infection.
The outcomes analysis related to the cost of PRP along
with management of sternal wounds is interesting be-
cause deep wound infections are so much more expen-
sive than the cost of PRP, once you have prevented one
of them, PRP sees a cost advantage. The Number of pa-
tients needed to be treated (NNT) and to break even







Infection Deep Sternal Wound 20 6 0.009
Superficial Sternal Wound 80 20 0.0001
Readmission 40 8 0.0001
Cost ($) Deep Sternal Wound 1,158,840 172,471 0.0001
Superficial Sternal Wound 98, 120 36,320 0.0087
Platelet Rich Plasma 0 385,000 0.0001
Total 1,256,960 593,791 0.012
The number of patients with deep and superficial infections along with the
cost of their management including the cost of the platelet rich plasma
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and combined. However, because the cost of treating the
superficial wounds is so low, PRP is always more expen-
sive. If the NNT was more like 3.5 instead of 17 for super-
ficial wounds, then PRP would be less costly as soon as
the first infection occurred.
There are a number limitations to this study including
that it is not a randomized blinded multi-center study.
However with the large sample size, the key points are
outcomes and costs which can be validated and bring
value to the healthcare of cardiac surgery patients. Wound
related issues are examined by a number of different
healthcare providers including nurse practitioners, phys-
ician assistants, primary care physicians, plastic surgeons
and cardiologists who are not administering the PRP or
primarily part of the study. This helps to minimize bias
which can occur if the investigator is always the same per-
son evaluating the wound related issues. The patients were
not match as part of this study and the entire population
of patients undergoing sternotomy were evaluated. There
are a number of confounding variables which may be
identified. However with a sample size of 2000 patients
and including all surgeons in study along with residents
and fellows helping close the sternotomies this provides
real world management of cardiac surgery patients. The
costs are derived directly from the hospital and financial
analysts who are also not directly part of study. As the
Centers for Medicaid and Medicare Services do not reim-
burse for the costs incurred during the treatment of DSWI
the findings of this study outweigh its limitations.
Conclusion
This study demonstrates that the routine use of PRP re-
duces the incidence of DSWI and SSWI along with the
overall costs for management resulting in absolute risk
reduction of 7.41 %. For the 2000 patients included in
this study, the application of PRP during surgical closure
was found to be safe and significantly reduced postoper-
ative infection rates in the treatment group. PRP is a
safe, simple and reproducible therapy that appears to
provide both a clinical and a financial benefit to patients
undergoing sternotomy for cardiac surgery. The addition
of PRP to all sternal closure after cardiac surgery brings
value by improving care and reducing costs.
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